20-F: FSD Pharma and Celly Nutrition Corp. Announce Arrangement Agreement

FSD Pharma and Celly Nutrition Corp. enter into an arrangement agreement for a reorganization transaction.

Summary

• FSD Pharma and Celly Nu have agreed to a reorganization transaction via a statutory plan of arrangement under the OBCA.
• The board of directors of FSD Pharma has determined the consideration to be received by securityholders is fair and in the best interests of the corporation.
• The arrangement involves FSD Pharma undertaking a reorganization transaction as detailed in the agreement and the Plan of Arrangement.
• FSD Pharma will prepare and send a management information circular to securityholders containing disclosure about the arrangement and prospectus-level disclosure about Celly Nu.
• The parties intend to carry out the arrangement in reliance on the exemption from registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof.
• The arrangement is subject to court approval and securityholder approval.
• The outside date for the arrangement is December 31, 2023.
• FSD Pharma owns 200,000,000 Celly Nu Shares beneficially and of record, free and clear of all Encumbrances.

Sentiment

Score: 7

Explanation: The document is a formal agreement, so the sentiment is neutral. However, the board's belief that the arrangement is in the best interests of the corporation suggests a slightly positive outlook.

Positives

• The board of directors of FSD Pharma believes the arrangement is in the best interests of the corporation.
• The arrangement allows FSD Pharma securityholders to receive consideration.
• The arrangement is structured to comply with U.S. securities laws, potentially simplifying the process for U.S. securityholders.

Negatives

• The arrangement is subject to court and securityholder approval, introducing uncertainty.
• The arrangement may involve income tax withholding.
• The arrangement could be terminated under certain conditions.

Risks

• The arrangement may not receive the necessary approvals.
• Laws or regulations could interfere with the completion of the plan of arrangement.
• A material adverse effect could impact FSD Pharma or the securityholders if the plan of arrangement is completed.
• The company is responsible for all costs associated with the arrangement and the meeting, and the preparation of the related documentation, including the Circular and all items identified in Section 2.4.

Future Outlook

The document outlines the steps and conditions required to effect the arrangement, but does not provide specific financial forecasts or projections.

Management Comments

• The board of directors of FSD Pharma has determined that the consideration to be received by the holders of Class A Shares, Class B Shares, and FSD Pharma Distribution Warrants is fair to such FSD Pharma Securityholders and that the Arrangement is in the best interests of the Corporation.

Industry Context

This announcement reflects a strategic move by FSD Pharma to reorganize its assets, potentially to focus on core business areas or unlock value for shareholders. It's important to consider this in the context of the broader pharmaceutical and biotechnology industry, where companies often restructure to optimize their portfolios.

Stakeholder Impact

• Shareholders will receive consideration as part of the arrangement.
• The arrangement is intended to be fair to all securityholders.
• The arrangement could impact the value of FSD Pharma securities.

Next Steps

• FSD Pharma will apply to the Court for an Interim Order.
• FSD Pharma will prepare and send the Circular to securityholders.
• FSD Pharma Securityholders will vote on the Arrangement Resolution at the Meeting.
• FSD Pharma will apply to the Court for the Final Order.
• The Parties will file the Articles of Arrangement with the OBCA Director.

Key Dates

Keywords

arrangement agreement, FSD Pharma, Celly Nu, reorganization, securityholders, OBCA, Section 3(a)(10), securities